Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-A18: pembrolizumab plus chemoradiotherapy in high-risk locally advanced cervical cancer
2022-501972-25-00Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab and cisplatin in Cervical Cancer (CC) (2 arms), sponsored by Merck & Co. Primary endpoints: Progression-free survival and Overall survival. Started May 2024; status: completed.
02
Drugs
pembrolizumabcisplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2022-501972-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501972-25-00.